HC Wainwright restated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a report released on Monday morning. The brokerage currently has a $20.00 price objective on the biopharmaceutical company’s stock.

ABEO has been the subject of a number of other reports. Maxim Group set a $17.00 price objective on Abeona Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 16th. FBR & Co restated a buy rating on shares of Abeona Therapeutics in a report on Friday, May 26th. Cantor Fitzgerald restated a buy rating and set a $21.00 target price on shares of Abeona Therapeutics in a report on Tuesday, June 6th. Zacks Investment Research cut Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, August 22nd. Finally, BidaskClub upgraded Abeona Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $18.50.

Shares of Abeona Therapeutics (NASDAQ ABEO) opened at 16.20 on Monday. The company has a 50-day moving average of $10.74 and a 200 day moving average of $7.22. The firm’s market cap is $652.65 million. Abeona Therapeutics has a 12-month low of $4.05 and a 12-month high of $17.90.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. Equities analysts predict that Abeona Therapeutics will post ($0.68) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/22/hc-wainwright-reaffirms-buy-rating-for-abeona-therapeutics-inc-abeo.html.

Several large investors have recently added to or reduced their stakes in ABEO. State Street Corp bought a new position in shares of Abeona Therapeutics during the 2nd quarter valued at about $1,900,000. Northern Trust Corp raised its position in Abeona Therapeutics by 406.3% in the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after buying an additional 206,775 shares during the last quarter. Highbridge Capital Management LLC raised its position in Abeona Therapeutics by 23.5% in the 1st quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock valued at $3,408,000 after buying an additional 129,811 shares during the last quarter. Vanguard Group Inc. raised its position in Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after buying an additional 108,730 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Abeona Therapeutics by 869.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 104,038 shares during the last quarter. Institutional investors and hedge funds own 38.24% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.